| Literature DB >> 29782633 |
Gabriela Sevignani1, Giovana Memari Pavanelli1, Sibele Sauzem Milano1, Bianca Ramos Ferronato2, Maria Aparecida Pachaly1, Hae Ii Cheong3, Mauricio de Carvalho2, Fellype Carvalho Barreto1.
Abstract
MYH9-related disease is an autosomal dominant disorder caused by mutations of the MYH9 gene, which encodes the non-muscle myosin heavy chain IIA on chromosome 22q12. It is characterized by congenital macrothrombocytopenia, bleeding tendency, hearing loss, and cataracts. Nephropathy occurs in approximately 30% of MYH9-related disease in a male patient carrier of a de novo missense mutation in exon 1 of the MYH9 gene [c.287C > T; p.Ser(TCG)96(TTG)Leu]. He presented all phenotypic manifestations of the disease, but cataracts. Renal alterations were microhematuria, nephrotic-range proteinuria (up to 7.5 g/24h), and rapid loss of renal function. The decline per year of the glomerular filtration rate was 20 mL/min/1.73m2 for five years. Blockade of the renin-angiotensin system, the only recommended therapy for slowing the progression of this nephropathy, was prescribed. Although MYH9-related disease is a rare cause of glomerulopathy and end-stage renal disease, awareness of rare genetic kidney disorders is essential to ensure accurate diagnosis and proper management of orphan disease patients.Entities:
Mesh:
Year: 2018 PMID: 29782633 PMCID: PMC6533988 DOI: 10.1590/2175-8239-jbn-3879
Source DB: PubMed Journal: J Bras Nefrol ISSN: 0101-2800